Merck Revamps Research with Artificial Intelligence

Pharmaceutical giant Merck & Co. is reshaping its clinical research operations to reduce friction and improve efficiency. The company is not simply adding artificial intelligence as a productivity tool but rebuilding the underlying infrastructure to support AI integration.

The pharmaceutical industry has long operated with caution. Clinical research is heavily regulated and operationally complex, built around systems that minimize risk rather than accelerate change. That approach has left the sector “lagging in modernization,” according to Jennifer Sheller, Merck’s senior vice president and head of global clinical trial operations.

Sheller described the existing setting as a “spaghetti architecture” — fragmented data environments stitched together through countless point-to-point integrations. To address this, Merck launched “Zero Gravity,” a multi-year internal initiative to harmonize clinical trial data before layering AI systems on top. This sequencing reflects a broader reality: AI implementation often fails when companies treat it as a standalone technology project instead of an operational redesign challenge.

Most organizations do not suffer from a shortage of AI tools. They suffer from fragmented systems, inconsistent data, and duplicated workflows that prevent AI from operating effectively at scale. Merck appears to understand that the long-term competitive advantage will not come from deploying the most AI models but from building an operational ecosystem where data, automation, governance, and human expertise work together continuously.

Targeting Inefficiencies

One of the clearest examples of this strategy is patient recruitment. Precision medicine trials increasingly require patients with highly specific mutations or disease characteristics, making recruitment extraordinarily difficult. Historically, healthcare staff manually reviewed records and patient histories to identify potential candidates, a slow process that often produced inconsistent outcomes.

Sheller noted that roughly 20% of activated clinical trial sites never enroll a single patient despite requiring months of setup work involving contracts, ethics approvals, equipment verification, and staffing. That exposes a hidden inefficiency embedded throughout the clinical trial system. AI-driven recruitment is therefore not simply about speed. It is about reducing wasted infrastructure investment across a global research network.

Merck is using AI systems to analyze electronic health records and unstructured medical data to identify trial candidates more efficiently. On the surface, this looks like a straightforward automation story. Strategically, however, it addresses a much larger economic problem inside pharmaceutical research.

This shift in focus has practical consequences for the research ecosystem. When operational friction is reduced, resources can be redirected toward scientific discovery and patient care rather than administrative overhead. The ability to identify suitable candidates quickly allows sites to remain active and productive, ensuring that months of setup and compliance work result in actual patient enrollment rather than dormant infrastructure.

Governance and Oversight

The company is also using generative AI primarily to accelerate lower-risk operational work such as document drafting, meeting summaries, and workflow monitoring. Rather than removing scientific oversight, the company is attempting to reduce the administrative burden surrounding it.

Merck appears unusually realistic about AI limitations. Throughout the discussion, Sheller emphasized the importance of “human in the loop” oversight. Clinical trials involve patient safety monitoring, adverse event reporting, scientific interpretation, and regulatory accountability that cannot simply be delegated to probabilistic systems.

Merck’s approach suggests the company views governance as a strategic capability rather than a regulatory burden. Sheller described internal governance systems designed to assess AI validation methods, quality controls, privacy safeguards, and oversight requirements before deployment.

That positioning matters because the pharmaceutical industry may be entering a period where governance quality becomes a competitive differentiator. Companies that build trusted AI systems early could gain regulatory credibility and operational flexibility that competitors struggle to replicate later. In healthcare, trust directly affects approvals, partnerships, and long-term scalability.

The Path Forward

The next major battleground may involve direct integration between electronic health records and clinical research systems. Sheller pointed to the growing opportunity around using AI and natural language processing to move unstructured healthcare data directly into research ecosystems. If successful, that could dramatically reduce duplicate data entry and improve trial efficiency.

What makes Merck’s AI strategy notable is not simply that the company is adopting artificial intelligence. Nearly every major enterprise now claims to be doing that. What differentiates Merck is the recognition that AI transformation is fundamentally an institutional redesign problem. The company is rebuilding workflows, governance systems, operational processes, and workforce structures simultaneously.

For pharmaceutical companies, trust remains the foundation underneath every clinical trial, regulatory submission, and patient relationship. Merck’s strategy suggests the company understands that AI in healthcare will succeed not through disruption alone, but through modernization that strengthens confidence while improving operational speed.